|
|
|
16.06.25 - 19:03
|
PureTech Health: Results of Annual General Meeting (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Monday, June 16, 2025.
All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.
Resolutions
For
%
Against
%
Withheld
Total votes cast
001. To approve the Company's Annual Report and Accounts for year ended 31 December 2024
161,252,066
99.97%
43,159
0.03%
43,897
161,295,225
002. To approve the Directors' Remuneration Report
87,191,034
72.49%
33,087,512
27.51%
41,060,576
120,278,546
003. To re-elect Ms. Sharon Barber-Lui as a Director
161,168,598
99.90%
165,990
0.10%
4,534
161,334,588
004. To re-elect Dr. Bharatt Chowrira as a Director
159,345,453
98.77%
1,989,135
1.23%
4,534
161,334,588
005. To elect Dr. Michele Holcomb as a Director
159,890,727
99.90%
153,630...
|
|
|
|
|
30.04.25 - 08:03
|
PureTech Announces Annual Results for Year Ended December 31, 2024 (Business Wire)
|
|
|
Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million
Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 2027
As of March 31, 2025, PureTech level cash, cash equivalents and short-term investments were $339.1 million5
Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its r...
|
|
|
23.04.25 - 08:03
|
PureTech Health: Notice of Results (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025.
A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics a...
|
|
|
09.04.25 - 08:06
|
PureTech Appoints Peel Hunt as Joint UK Corporate Broker (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of th...
|
|
|
|
|
07.04.25 - 18:21
|
PureTech Health plc Statement Regarding Press Speculation (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--The Board of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) notes the recent press speculation and confirms that it is in discussions with Nordic Capital Epsilon SCA, SICAV-RAIF (acting through its general partner Nordic Capital Epsilon GP SARL) ("Nordic Capital") regarding a possible cash offer to acquire the entire share capital of the Company.
A further announcement will be made as and when appropriate. There can be no certainty that any firm offer will be made for the Company, nor as to the terms on which any firm offer might be made.
In accordance with Rule 2.6(a) of the Code, Nordic Capital is required, by no later than 5.00 p.m. (London time) on 5 May 2025, being 28 days after the date of this announcement, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement...
|
|
|
11.03.25 - 12:06
|
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair (Business Wire)
|
|
|
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, (“Seaport”) a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert “Bob” J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of Directors, such as FORTUNE 500 companies like BioMarin (NASDAQ: BMRN), where he also chairs the Audit Committee, and Henry Schein (NASD...
|
|
|
|
|
16.12.24 - 10:39
|
UK′s PureTech Health gains as lung drug meets main goal of mid-stage trial (Reuters EN)
|
|
|
BUZZ-UK's PureTech Health gains as lung drug meets main goal of mid-stage trial ** Shares of London-listed PureTech Health PRTC.L jump 5.9% at 172.4p after company's lung disease drug met main and secondary goals of a mid-stage trial ** Deupirfenidone (LYT-100), a potential treatment for idiopathic pulmonary fibrosis (IPF), slowed lung function dec...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
